Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy
When severely immunodeficient HIV/HCV co-infected patients are treated with antiretroviral therapy, it is important to know whether HCV-specific antibody responses recover and whether antibody profiles predict the occurrence of HCV-associated immune restoration disease (IRD). In 50 HIV/HCV co-infect...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Academic Press
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/21202 |
| _version_ | 1848750524477734912 |
|---|---|
| author | Lee, S. Saraswati, H. Yunihastuti, E. Gani, R. Price, Patricia |
| author_facet | Lee, S. Saraswati, H. Yunihastuti, E. Gani, R. Price, Patricia |
| author_sort | Lee, S. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | When severely immunodeficient HIV/HCV co-infected patients are treated with antiretroviral therapy, it is important to know whether HCV-specific antibody responses recover and whether antibody profiles predict the occurrence of HCV-associated immune restoration disease (IRD). In 50 HIV/HCV co-infected patients, we found that antibody reactivity and titres of neutralising antibodies (nAb) to JFH-1 (HCV genotype 2a virus) increased over 48 weeks of therapy. Development of HCV IRD was associated with elevated reactivity to JFH-1 before and during the first 12 weeks of therapy. Individual analyses of HCV IRD and non-HCV IRD patients revealed a lack of an association between nAb responses and HCV viral loads. These results showed that increased HCV-specific antibody levels during therapy were associated with CD4+ T-cell recovery. Whilst genotype cross-reactive antibody responses may identify co-infected patients at risk of developing HCV IRD, neutralising antibodies to JFH-1 were not involved in suppression of HCV replication during therapy. |
| first_indexed | 2025-11-14T07:38:12Z |
| format | Journal Article |
| id | curtin-20.500.11937-21202 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:38:12Z |
| publishDate | 2014 |
| publisher | Academic Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-212022017-09-13T13:54:26Z Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy Lee, S. Saraswati, H. Yunihastuti, E. Gani, R. Price, Patricia Genotype cross-reactive neutralising antibody Antiretroviral therapy HIV HCV When severely immunodeficient HIV/HCV co-infected patients are treated with antiretroviral therapy, it is important to know whether HCV-specific antibody responses recover and whether antibody profiles predict the occurrence of HCV-associated immune restoration disease (IRD). In 50 HIV/HCV co-infected patients, we found that antibody reactivity and titres of neutralising antibodies (nAb) to JFH-1 (HCV genotype 2a virus) increased over 48 weeks of therapy. Development of HCV IRD was associated with elevated reactivity to JFH-1 before and during the first 12 weeks of therapy. Individual analyses of HCV IRD and non-HCV IRD patients revealed a lack of an association between nAb responses and HCV viral loads. These results showed that increased HCV-specific antibody levels during therapy were associated with CD4+ T-cell recovery. Whilst genotype cross-reactive antibody responses may identify co-infected patients at risk of developing HCV IRD, neutralising antibodies to JFH-1 were not involved in suppression of HCV replication during therapy. 2014 Journal Article http://hdl.handle.net/20.500.11937/21202 10.1016/j.clim.2014.09.013 Academic Press restricted |
| spellingShingle | Genotype cross-reactive neutralising antibody Antiretroviral therapy HIV HCV Lee, S. Saraswati, H. Yunihastuti, E. Gani, R. Price, Patricia Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy |
| title | Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy |
| title_full | Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy |
| title_fullStr | Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy |
| title_full_unstemmed | Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy |
| title_short | Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy |
| title_sort | patients co-infected with hepatitis c virus (hcv) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to hcv during antiretroviral therapy |
| topic | Genotype cross-reactive neutralising antibody Antiretroviral therapy HIV HCV |
| url | http://hdl.handle.net/20.500.11937/21202 |